Weight-loss drugs have made big headlines in health over the past year, and Eli Lilly’s drug tirzepatide (known as Zepbound for obesity or Mounjaro for diabetes), which received U.S. Food and Drug Administration approval for treating obesity last November, is central to the conversation. Now the FDA is reviewing another of the company’s drugs, which would be a breakthrough for Alzheimer’s treatment. But having effective medications for diseases that affect so many isn’t truly useful unless they get into the hands of patients who need them. So in 2024, the company—which this year took the top spot as the world’s largest health care company by market cap—created LillyDirect to improve patients' access to the company’s drugs for obesity, migraine and diabetes. The program ships drugs directly to patients, automatically applies any co-pay assistance they are eligible to receive, and could result in lower overall costs to patients.
More Must-Reads from TIME
- Biden Drops Out of Presidential Race , Endorses Harris to Replace Him
- Why Biden Dropped Out
- The Chaos and Commotion of the RNC in Photos
- Why We All Have a Stake in Twisters’ Success
- 8 Eating Habits That Actually Improve Your Sleep
- Stop Feeling Bad About Sweating
- Welcome to the Noah Lyles Olympics
- Get Our Paris Olympics Newsletter in Your Inbox
Contact us at letters@time.com